Corvus Pharmaceuticals, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CRVS Nasdaq 2834 www.corvuspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Corvus Pharmaceuticals, Inc.

Companies Like Corvus Pharmaceuticals (NASDAQ:CRVS) Are In A Position To Invest In Growth - Jun 25th, 2025 7:14 am
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis - Jun 25th, 2025 6:00 am
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress - Jun 11th, 2025 5:00 am
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - Jun 4th, 2025 5:00 am
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - May 28th, 2025 2:01 pm
Spotlight On Top Penny Stocks For May 2025 - May 12th, 2025 6:05 am
Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? - May 9th, 2025 6:32 am
Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... - May 9th, 2025 1:41 am
Corvus: Q1 Earnings Snapshot - May 8th, 2025 2:39 pm
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results - May 8th, 2025 2:02 pm
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis - May 8th, 2025 2:01 pm
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 - Apr 23rd, 2025 2:08 pm
Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires? - Apr 22nd, 2025 4:47 pm
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors - Apr 9th, 2025 2:01 pm
Insider Buyers At Corvus Pharmaceuticals Sitting On US$1.3m Profit - Mar 26th, 2025 7:11 am
Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... - Mar 26th, 2025 1:02 am
Corvus: Q4 Earnings Snapshot - Mar 25th, 2025 2:09 pm
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - Mar 25th, 2025 2:01 pm
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - Mar 20th, 2025 6:00 am
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - Mar 19th, 2025 2:01 pm